501. Acute Posterior Vitreous Detachment and Acute Vitreous Hemorrhage Appropriate Examination and Follow-up

Percentage of patients with a diagnosis of acute posterior vitreous detachment (PVD) and acute vitreous hemorrhage in either eye who were appropriately evaluated during the initial exam and were re-evaluated no later than two weeks.

This measure is to be submitted once per performance period for denominator eligible cases as defined in the denominator criteria. This measure is intended to reflect the quality of services provided for patients with a diagnosis of acute posterior vitreous detachment (PVD) with acute vitreous hemorrhage. This measure may be submitted by MIPS-eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Document the diabetic condition:

  1. Select a posterior vitreous detachment Diagnosis.
  2. Select a counseling PVD Plan and tap Save.
  3. Add vitreous hemorrhage as an Associate Dx.
  4. Locate the counseling plan and tap Resume.
  5. Select the appropriate options from the Quality 501 drop-downs.
  6. Document the rest of the visit and Finalize.

Alternatively, code quality with a special plan:

  1. Document a Diagnosis and Plan as you normally would.
  2. Tap Special Plans and select MIPS.
  3. From Popular Plans, select MIPS Quality and tap Save.
  4. Locate the MIPS Quality plan and tap Resume.
  5. Tap the PVD tab.
  6. Select the appropriate options from the Quality 501 drop-downs.
  7. Tap Done.
  8. Document the rest of the visit and Finalize.

Eyefinity products and documentation refer to the MIPS quality numbers. Other measure numbering systems are listed here for your reference.

Quality 501
NQF —
CMS —
  • Registry
  • AAO IRIS
  • MVP

This topic describes how points are calculated for this measure. To learn more about scoring, go to Scoring.

Benchmarks are displayed here as both a chart and a table. The chart gives you a visual representation and helps you quickly compare benchmarks across different reporting methods. The table lists the specific benchmark criteria for each available reporting method.

 

Submission Method 3rd Decile 4th Decile 5th Decile 6th Decile 7th Decile 8th Decile 9th Decile 10th Decile
Registry* — — — — — — — —
AAO IRIS* — — — — — — — —
MVP* — — — — — — — —

* Benchmarking data for this submission method was unavailable at the time of publication.

Patients regardless of age and eligible encounter during the performance period:

92002, 92004, 92012, 92014, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99242, 99243, 99244, 99245

AND with a diagnosis of PVD in either eye:

H43.811, H43.812, H43.813, H43.819

AND acute PVD:

M1337

AND acute vitreous hemorrhege:

M1333

Denominator Exclusions

Patients with a postoperative encounter of the eye with the acute PVD within two weeks before the initial encounter or two weeks after initial acute PVD encounter:

M1334

OR encounters conducted via telehealth:

M1442

Denominator Exceptions

Documentation of patient reason(s) for not having a follow up exam (e.g., inadequate time for follow up):

M1335

If the initial exam occurs between December 17 and December 31 of the performance period and the patient is not able to be seen for follow-up within the performance period, it would be appropriate to report the denominator exception for inadequate time for follow-up.

Patients who were appropriately evaluated during the initial exam and were re-evaluated no later than two weeks:

Performance Met

Patients who were appropriately evaluated during the initial exam AND were re-evaluated no later than two weeks:

M1336

Performance Not Met

Patients who were not appropriately evaluated during the initial exam and/or who were not re-evaluated within two weeks:

M1332